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Abstract Sleep disturbances are very prevalent in
Huntington’s disease (HD) patients and can substantially
impair their quality of life. Accumulating evidence sug-
gests considerable dysfunction of the hypothalamic sup-
rachiasmatic nucleus (SCN), the biological clock, in both
HD patients and transgenic mouse models of the disease.
As melatonin has a major role in the regulation of sleep and
other cyclical bodily activities and its synthesis is directly
regulated by the SCN, we postulated that disturbed SCN
function is likely to give rise to abnormal melatonin
secretion in HD. Therefore, we compared 24 h melatonin
secretion proﬁles between early stage HD patients and
age-, sex- and body mass index-matched controls. Although
mean diurnal melatonin levels were not different between
the two groups (p = 0.691), the timing of the evening rise
in melatonin levels was signiﬁcantly delayed by more than
01:30 h in HD patients (p = 0.048). Moreover, diurnal
melatonin levels strongly correlated with both motor
(r =- 0.70, p = 0.036) and functional impairment
(r =? 0.78, p = 0.013). These ﬁndings suggest a delayed
sleep phase syndrome-like circadian rhythm disorder in
early stage HD patients and suggest that melatonin levels
may progressively decline with advancing disease.
Keywords Huntington’s disease  Melatonin  Sleep 
Circadian rhythm  Hypothalamus
Introduction
Huntington’s disease (HD) is an autosomal dominant
neurodegenerative disorder caused by an expanded CAG
repeat size in the gene encoding the protein huntingtin [4].
The disease is characterized by motor impairment, cogni-
tive deterioration, behavioral problems and progressive
weight loss [4]. With an estimated prevalence of nearly
90%, disturbed sleep is also a prominent feature of the
disease, substantially impairing the quality of life of both
patients and caregivers [20]. Sleep disturbances in HD
patients include an increased sleep onset latency, frequent
nocturnal awakenings, reduced sleep efﬁciency, delayed
and shortened rapid eye movement sleep, and increased
periodic leg movements [1, 8, 22, 24]. Moreover, wrist
actigraphy studies indicate circadian rhythm disturbances
in HD patients, which are mirrored in the most widely used
transgenic mouse model of the disease, the R6/2 mouse
[10, 14, 15]. The R6/2 mice show progressive disruption of
the day–night activity patterns, with increased daytime
activity and a concurrent decrease in nocturnal activity,
eventually leading to a complete disintegration of the cir-
cadian behavior [14, 15]. Interestingly, disrupted circadian
behavior in these mice is accompanied by marked dys-
regulation of expression of a number of circadian clock
genes in the hypothalamic suprachiasmatic nucleus (SCN),
the principal rhythm generating system in mammals
[12, 14, 15]. Furthermore, we recently demonstrated an
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DOI 10.1007/s00415-009-5196-1increased amplitude of the diurnal cortisol proﬁle as well as
an increased rate of early day cortisol production in HD
patients, both of which are also consistent with SCN dys-
function in HD [3].
Melatonin is a hormone that is primarily secreted at
night by the pineal gland and has a major role in the
regulation of sleep and other cyclical bodily activities [5, 16].
Melatonin synthesis is directly regulated by the SCN via a
multisynaptic pathway in response to the environmental
light/dark cycle, and thus, melatonin is considered an
endogenous humoral synchronizer that signals ‘time of
day’ to all tissues throughout the body [5]. Conversely, the
two major melatonin receptors, MT1 and MT2 receptors,
are abundantly expressed in the SCN and are thought to
mediate melatonin’s sleep-promoting and circadian phase-
shifting effects [5]. Therefore, we postulated that disturbed
SCN function in HD is likely to give rise to abnormal
melatonin secretion, which in turn could contribute to
impaired sleep and circadian rhythm disturbances in HD
patients. In addition, as apart from its timekeeping func-
tions, melatonin also has strong antioxidative properties—
abnormal melatonin secretion may also inﬂuence the neu-
rodegenerative process underlying HD. In order to test
these hypotheses, we: (1) compared 24 h plasma melatonin
concentration proﬁles between early stage, medication-free
HD patients and healthy matched controls, and (2) assessed
the association between mean diurnal melatonin levels and
clinical phenotype.
Subjects and methods
Subjects
Nine early stage HD patients and nine healthy control
subjects, matched for age, sex, and body mass index
(BMI), were enrolled in the study. Clinical details are
summarized in Table 1. The clinical diagnosis of HD was
made by a neurologist specialized in movement disorders
(R.A.C.R.). The uniﬁed Huntington’s disease rating scale
(UHDRS) was used to assess HD symptoms and signs [9].
All subjects were free of medication, except one HD
patient who discontinued paroxetine use 3 weeks prior to
the study. Written informed consent was obtained from all
subjects. The study was approved by the ethics committee
of the Leiden University Medical Center.
Clinical protocol
Subjects were admitted to the Clinical Research Center for
24 h blood sampling. Two women (one patient and one
control) were postmenopausal, the other women were stud-
ied in the early follicular phase of their menstrual cycles.
A cannula was inserted into an antecubital vein 45 min
before the start of blood sampling at16:30 h. Bloodsamples
were collected with S-monovetten (Sarstedt, Etten-Leur,
The Netherlands) from a three-way stopcock that was
attached to a 0.9% NaCl and heparin (1 U ml
-1) infusion
(500 ml/24 h) to keep the cannula from clotting. Sampling
wasperformedthroughalonglinetopreventsleepdisruption
by investigative manipulations. During 24 h, blood was
collected in serum tubes every hour. Blood was allowed to
clot and, within 60-min of sampling, centrifuged at
4,000 rotations min
-1 at 4C for 20 min, and plasma was
stored at -80C until assay. Three standardized meals were
served at 09:00, 13:00, and 19:00 h (Nutridrink,
1.5 kcal ml
-1, 1,500–1,800 kcal d
-1; macronutrient com-
position per 100 ml: protein, 5 g; fat, 6.5 g; carbohydrate,
17.9 g; Nutricia, Zoetermeer, The Netherlands). Twenty-
four hour urine was collected for the determination of cre-
atinine and catecholamine concentrations. Subjects
remained sedentary except for bathroom visits. No daytime
naps were allowed. Lights were switched off at 23:00 h and
back on at 07:30 the next morning.
Assays
Plasma melatonin was measured by radioimmunoassay
(Labor Diagnostika Nord GmbH & Co. KG, Nordhorn,
GER). The detection limit of the assay was 2 pg mL
-1. The
intra-assay and interassay variations ranged from 9.8 to
12.3% and from 9.6 to 16.2%, respectively. Samples from
each patient and matched control were handled in the same
run. Urine creatinine was measured by a fully automated P
800 Modular system (Roche, Almere, The Netherlands).
Urinary epinephrine, norepinephrine and dopamine con-
centrations were assessed by high performance liquid
Table 1 Characteristics of the study population
HD patients
a Controls
a p-value
b
Male/female 6/3 6/3 –
Age (year) 47.1 (3.4) 48.6 (3.3) 0.691
BMI 24.1 (1.0) 24.3 (0.6) 0.691
Mutant CAG repeat size 44.4 (1.0) – –
Disease duration (year) 5.7 (1.1) – –
UHDRS motor score 22.2 (6.0) – –
TFC score 11.7 (0.7) – –
Functional assessment 23.3 (0.7) – –
Independence score 94.4 (2.8) – –
BMI body mass index; FAS functional assessment; TFC total func-
tional capacity; UHDRS uniﬁed Huntington’s disease rating scale
a Values are indicated as mean (SE)
b Differences between groups were assessed by the Mann–Whitney
U-test
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123chromatography with electron capture detection (ESTA-
Coulochem, Chelmsford, MA, USA).
Analysis of melatonin proﬁles
Individual diurnal variations of plasma melatonin levels
were quantiﬁed by a best-ﬁt curve obtained using locally
weighted linear regression with a Gaussian kernel and a
regression window of 4 h as previously described [11]. For
each melatonin proﬁle the nadir and the acrophase were
deﬁned as the minimum and maximum of the best-ﬁtting
curve, while the amplitude was deﬁned as half of the dif-
ference between the acrophase and nadir values. The onset
of the melatonin rise was deﬁned as the timing of the ﬁrst
plasma level exceeding the mean ? 3 standard deviations
(SDs) of baseline levels recorded over the 1030–1430
period, not followed to lower concentrations before the
acrophase. The melatonin offset was deﬁned as the timing
of the last value occurring after the acrophase that excee-
ded ?3 SDs of the baseline values [11].
Statistical analysis
Results are expressed as mean ± standard error (SE)
unless otherwise speciﬁed. The non-parametric Mann–
Whitney U-test was used to assess group differences.
Spearman’s correlation coefﬁcient was applied to assess all
correlations. All tests were two-tailed and signiﬁcance
level was set at p\0.05. Statistical analyses were per-
formed using SPSS for Windows (release 16.0, SPSS, Inc.,
Chicago, IL).
Results
Subjects
The HD and the control group did not differ with respect to
age, sex, and BMI (all p C 0.691, Table 1). There were
also no signiﬁcant differences in urinary creatinine, epi-
nephrine, norepinephrine and dopamine levels (all
p C 0.10).
Melatonin proﬁles
Mean 24 h melatonin levels were not signiﬁcantly different
between HD patients and controls (24.8 ± 5.4 vs.
22.7 ± 2.8 pg mL
-1, p = 0.691; Fig. 1). Also the acro-
phase and nadir concentrations, as well as the amplitude of
the diurnal melatonin proﬁle were not signiﬁcantly different
between the two groups (p C 0.857; Table 2). In one HD
patient, however, the diurnal melatonin proﬁle was extre-
mely irregular and at no point did melatonin concentrations
rise above three standard deviations of the mean baseline
values (this subject also happened to be the most severely
affectedpatientwithscoresof63and7ontheUHDRSmotor
and total functional capacity subscales, respectively). Con-
sequently, melatonin onset, offset and duration could not be
deﬁned inthis subject;therefore,for subsequent comparison
oftheseparametervaluesbetweenthetwogroups,thedataof
the subject and the matched control subject were excluded
from the analyses. Melatonin onset time was signiﬁcantly
delayed in HD patients compared with controls (00:30 h ±
22 minvs.22:52 h ± 37 min,p = 0.048).Melatoninoffset
time, however, was similar between the two groups
Fig. 1 Mean 24 h melatonin levels in HD patients and matched
controls. The diurnal melatonin rise was signiﬁcantly delayed in HD
patients by about 01:30 h (p = 0.048). The black bar on the abscissa
indicates the dark period (23:00–7:30 h)
Table 2 Melatonin secretion characteristics in HD patients and
controls
HD patients
a Controls
a p-
value
b
Mean 24 h levels (pg mL
-1) 24.8 (5.4) 22.7 (2.8) 0.601
Acrophase conc. (pg mL
-1) 76.6 (20.4) 60.1 (9.7) 0.860
Nadir conc. (pg mL
-1) 5.8 (0.9) 5.8 (0.7) 0.857
Amplitude (pg mL
-1) 35.4 (9.9) 27.2 (4.8) 0.895
Onset time (hh:mm) 00:30 (00:22) 22:52 (00:40) 0.048
*
Offset time (hh:mm) 07:30 (00:48) 08:22 (00:21) 0.478
Nocturnal duration (h) 7.0 (1.0) 9.5 (0.8) 0.063
* p\0.05
a Values are indicated as mean (SE)
b Differences between groups were assessed by the Mann–Whitney
U-test
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123(Table 2). Consequently, there was also a trend for a shorter
duration of the nocturnal plasma melatonin plateau in HD
patients (6.2 ± 1.2 vs. 9.1 ± 0.8 h, p = 0.063).
Melatonin levels and clinical phenotype
In HD patients, mean 24 h melatonin levels signiﬁcantly
correlated with UHDRS motor score (r =- 0.70, p =
0.036), total functional capacity (r =? 0.78, p = 0.013),
and independence score (r =? 0.88, p = 0.002), but not
with mutant CAG repeat size (r =? 0.18, p = 0.645).
Discussion
Here we present the ﬁrst detailed description of diurnal
melatonin proﬁles in HD patients. We show that the timing
of the evening rise in melatonin levels is signiﬁcantly
delayed by more than 01:30 h in these patients compared
with matched control subjects. Moreover, despite similar
mean diurnal melatonin levels between our early stage HD
patients and controls, we found strong inverse associations
between mean diurnal melatonin levels and both motor and
functional disability in these patients, suggesting that
decreases in melatonin levels are likely to become more
pronounced in the later stages of the disease.
Delayed onset of melatonin secretion in HD patients is
reminiscent of a delayed sleep phase syndrome (DSPS)-
like circadian rhythm disorder [25]. The pathophysiologi-
cal basis of DSPS is assumed to lie in a slower endogenous
clock with an abnormally long intrinsic circadian period-
icity, resulting in a delayed phase position of the overt
circadian rhythms, including those of melatonin, cortisol
and core body temperature [25]. Interestingly, recently we
also found an increased rate of early day cortisol produc-
tion in HD patients, which may also be a manifestation of
delayed circadian rhythms in HD [3]. Circadian rhythm
disturbances in HD are likely to stem directly from
pathology within the SCN molecular oscillation, caused
either by the toxic effects of mutant huntingtin locally and/
or arising from dysfunction of brain circuitry afferent to the
SCN [14, 15]. In favour of local pathology is the detection
of neuronal inclusions of mutant huntingtin in the SCN of
HD patients [2], as well as the ﬁnding of SCN dysfunction
at both mRNA and protein level in R6/2 mice, with
reduced levels of the positive regulator mBmal1 and trun-
cated peak expression of its target genes mPer1, mPer2,
and mProk2 [14]. However, intact oscillation of SCN
neurons from R6/2 mice in vitro, when released from the
pathological context, is consistent with an afferent cause of
SCN dysfunction in HD [15]. Alternatively, impaired
expression and/or function of the melatonin receptors in
HD could play a role, particularly the MT2 receptor
subtype which is enriched in the SCN and is known to be
involved in phase-shifting of the biological clock [17].
Regardless of the cause of diurnal rhythm disturbances in
HD, however, restoration of circadian rhythms by phar-
macological imposition of sleep has been shown to
improve cognitive decline in R6/2 mice, suggesting that a
similar strategy may be beneﬁcial to HD patients. As our
ﬁndings indicate a DSPS-like phenotype in early stage HD,
another approach that may be evaluated in these patients is
to treat them with melatonin and/or bright light at the
appropriate times so as to phase advance the clock [13, 25].
The administration of melatonin at the subjective dusk, and
the use of bright light at the subjective dawn and avoidance
of light in the subjective evening, could be used to phase
advance the clock [13, 25].
Interestingly, we also found that mean diurnal mela-
tonin levels in HD patients decreased with increasing
severity of the clinical phenotype, suggesting that mela-
tonin levels may decline substantially with advancing
disease course. Progressive abnormalities in the metabo-
lism of the melatonin precursor tryptophan may account
for this association [7, 19], although additional investi-
gations are needed to pinpoint the exact underlying
metabolic pathways. Numerous studies have shown the
ability of melatonin and its kynuramine metabolites to
increase the survival of neurons under conditions of
enhanced oxidative stress [18]. Therefore, declining
melatonin levels may contribute to the progressive neu-
rodegeneration in HD, and conversely, exogenous mela-
tonin supplementation may be of beneﬁt to HD patients.
In fact, melatonin can antagonise the cytotoxic properties
of both quinolinic acid and 3-nitropropionic acid, the
administration of which is used to model HD induced
pathology [6, 21]. Moreover, recently it was demon-
strated that melatonin can potently inhibit mitochondrial
cytochrome c release, which is known to activate
downstream cell death pathways, resulting in neuropro-
tection in a mutant huntingtin expressing striatal cell line
[23].
In conclusion, our ﬁndings suggest a DSPS-like circa-
dian rhythm disorder in early stage HD patients and indi-
cate that melatonin levels may progressively decline with
advancing disease. Therefore, strategies aimed at advanc-
ing the phase of the biological clock as well as melatonin
supplementation might be of beneﬁt to HD patients. First,
however, larger scale studies are needed to conﬁrm our
ﬁndings and to assess whether later stages of HD are also
accompanied by a similar circadian rhythm disorder.
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